BRPI0812403B8 - composição compreendendo proteína que carrega oxigênio baseada em porfirina modificada e uso da referida composição - Google Patents

composição compreendendo proteína que carrega oxigênio baseada em porfirina modificada e uso da referida composição

Info

Publication number
BRPI0812403B8
BRPI0812403B8 BRPI0812403A BRPI0812403A BRPI0812403B8 BR PI0812403 B8 BRPI0812403 B8 BR PI0812403B8 BR PI0812403 A BRPI0812403 A BR PI0812403A BR PI0812403 A BRPI0812403 A BR PI0812403A BR PI0812403 B8 BRPI0812403 B8 BR PI0812403B8
Authority
BR
Brazil
Prior art keywords
composition
oxygen
protein based
modified
carrying protein
Prior art date
Application number
BRPI0812403A
Other languages
English (en)
Inventor
Jon Reeder Brandon
Eric Cooper Christopher
Thomas Wilson Michael
Original Assignee
Univ Of Essex Enterprises Limited
Wivenhoe Tech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Essex Enterprises Limited, Wivenhoe Tech Limited filed Critical Univ Of Essex Enterprises Limited
Publication of BRPI0812403A2 publication Critical patent/BRPI0812403A2/pt
Publication of BRPI0812403B1 publication Critical patent/BRPI0812403B1/pt
Publication of BRPI0812403B8 publication Critical patent/BRPI0812403B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

proteínas globinas modificadas com via de transporte de elétron alterada. a presente invenção refere-se a uma proteína que carrega oxigênio baseada em porfirina modificada, tal como hemoglobina, a qual tem sido encontrada, em seu estado não-modificado para ter um sítio de baixa afinidade de transferência de elétron e uma alta afinidade de transferência de alétron entre um ferro hemo ferril e um redutor através de um ou mais aminoácidos protéicos. a invenção provê tais proteínas que compreendem uma modificação para elevar esta via.
BRPI0812403A 2007-06-29 2008-06-26 composição compreendendo proteína que carrega oxigênio baseada em porfirina modificada e uso da referida composição BRPI0812403B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0712685.7A GB0712685D0 (en) 2007-06-29 2007-06-29 Improvements relating to oxygen-carrying proteins (2)
PCT/GB2008/002199 WO2009004309A1 (en) 2007-06-29 2008-06-26 Modified globin proteins with altered electron transport pathway

Publications (3)

Publication Number Publication Date
BRPI0812403A2 BRPI0812403A2 (pt) 2014-12-02
BRPI0812403B1 BRPI0812403B1 (pt) 2019-08-27
BRPI0812403B8 true BRPI0812403B8 (pt) 2021-05-25

Family

ID=38420974

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812403A BRPI0812403B8 (pt) 2007-06-29 2008-06-26 composição compreendendo proteína que carrega oxigênio baseada em porfirina modificada e uso da referida composição

Country Status (9)

Country Link
US (1) US8609814B2 (pt)
EP (1) EP2170948B1 (pt)
JP (1) JP2010531659A (pt)
CN (1) CN101711255A (pt)
AU (1) AU2008272721B2 (pt)
BR (1) BRPI0812403B8 (pt)
CA (1) CA2690370A1 (pt)
GB (1) GB0712685D0 (pt)
WO (1) WO2009004309A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2858495A4 (en) 2012-04-30 2016-06-01 Dow Agrosciences Llc VEHICLES FOR ADMINISTERING A PESTICIDE COMPOSITION
GB201704006D0 (en) * 2017-03-13 2017-04-26 Univ Essex Modified globin proteins
EP3655019A4 (en) 2017-07-18 2021-04-21 Virtech Bio, Inc. BLUTER SUBSTITUTES CONTAINING HEMOGLOBIN AND PROCESS FOR THEIR PRODUCTION
GB201721503D0 (en) 2017-12-20 2018-01-31 Univ Essex Modified globin proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8711614D0 (en) * 1987-05-16 1987-06-24 Medical Res Council Proteins
US5884323A (en) * 1995-10-13 1999-03-16 3Com Corporation Extendible method and apparatus for synchronizing files on two different computer systems
EP0859789A1 (en) * 1995-10-23 1998-08-26 Rice University Hemoglobin mutants that reduce heme loss
GB0712683D0 (en) 2007-06-29 2007-08-08 Wivenhoe Technology Ltd Improvements relating to oxygen-carrying proteins(1)

Also Published As

Publication number Publication date
US8609814B2 (en) 2013-12-17
AU2008272721A1 (en) 2009-01-08
CN101711255A (zh) 2010-05-19
EP2170948A1 (en) 2010-04-07
GB0712685D0 (en) 2007-08-08
CA2690370A1 (en) 2009-01-08
JP2010531659A (ja) 2010-09-30
WO2009004309A1 (en) 2009-01-08
EP2170948B1 (en) 2016-11-02
US20100137189A1 (en) 2010-06-03
BRPI0812403A2 (pt) 2014-12-02
AU2008272721B2 (en) 2013-06-27
BRPI0812403B1 (pt) 2019-08-27

Similar Documents

Publication Publication Date Title
AR057614A1 (es) Composiciones y metodos para producir moleculas de union con antigeno hibridas y usos de las mismas
BR112012033295A2 (pt) polipeptídeos curtos e contendo d-aminoácido para conjugados terapêuticos e seu uso
BRPI0514340A (pt) formulações de estabilização
BRPI0620806B8 (pt) complexo e composição compreendendo um peptídeo e uma molécula carga, e uso da referida composição
BRPI0514411B8 (pt) formulação, e, método de produzir uma formulação
BRPI0610786B8 (pt) uso de um ou mais oligossacarídeos ácidos e neutros, e cisteína e/ou fonte de cisteína, e, composição alimentícia
WO2007035757A3 (en) Composition and method for treating iron deficiency anemia
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
AR056816A1 (es) Composicion con ácido docosapentenoico
MX2009010935A (es) Composiciones de alimentos secos.
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
BRPI0812403B8 (pt) composição compreendendo proteína que carrega oxigênio baseada em porfirina modificada e uso da referida composição
NO20033941L (no) Sammensetning som forbedrer aldersrelaterte fysiologiske mangler som forlenger levetiden
UA89798C2 (ru) Стабильный водный препарат антитела в гистидинацетатном буфере
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
BRPI0511067A (pt) processo para a formulação de formas de dosagem de dispersão rápida compreendendo pelo menos uma gelatina de peixe selecionada com base no peso molecular
BR112012027427A2 (pt) composições nutritivas e métodos para a mudança da nutrição parenteral para a nutrição enteral
ATE544780T1 (de) Hybrid-polypeptide mit eingefügten sequenzmotiven und ihre verwendungen
BRPI0707488B8 (pt) método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável
HK1083296A1 (en) Enteral composition for the prevention and/or treatment of sepsis
CY1115938T1 (el) Νεα συνθεση για αυξηση της bio-διαθεσιμοτητας της νεουρτουρινης (neurturin)
TR200400639T4 (tr) Donmaya-karşı proteinler, bunların üretimleri ve kullanımları
BRPI0516922A (pt) composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: UNIVERSITY OF ESSEX ENTERPRISES LIMITED (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF